A doctor and a patient connecting over the one-time-only infusion of ZOLGENSMA
The one-time-only dose to stop SMA progression
ZOLGENSMA® (onasemnogene abeparvovec-xioi) is a gene therapy for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA)1
Getting started with ZOLGENSMA
Complete the ZOLGENSMA Prescription and Patient Consent Forms for eligible patients to help with insurance and prescription-related processes.
ZOLGENSMA Prescription and Patient Consent Forms
Download
Patient support
The OneGene Program™, offered by Novartis Gene Therapies, is a comprehensive, individualized support program for families with pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) and their healthcare providers throughout the ZOLGENSMA treatment journey.
OneGene Program support includes:
- Answers to questions about ZOLGENSMA
- A dedicated, personalized support team focused on the needs of each family
- Verification of insurance benefits
- Coordination of financial assistance programs for eligible patients
Families can access the full range of OneGene Program support resources when the ZOLGENSMA Prescription Form and accompanying Patient Consent Form have been provided to the OneGene Program.
For questions call 1-855-441-GENE (4363),
Monday-Friday (8 AM to 8 PM ET)
For questions call 1-855-441-GENE (4363) – Monday-Friday (8 AM to 8 PM ET)
Discover more about ZOLGENSMA
Reference: 1. ZOLGENSMA [prescribing information]. Bannockburn, IL: AveXis, Inc; 2021.